Nektar Therapeutics (NKTR) Reports In-Line Q2 EPS
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $67.70 -3.78%
Revenue Growth %: -7.1%
Financial Fact:
Total revenue: 36.34M
Today's EPS Names:
CCEL, MHGU, PLG, More
Revenue Growth %: -7.1%
Financial Fact:
Total revenue: 36.34M
Today's EPS Names:
CCEL, MHGU, PLG, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of ($0.40), in-line with the analyst estimate of ($0.40). Revenue for the quarter came in at $22.7 million versus the consensus estimate of $21.49 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies upgrades Shopify to Buy on AI commerce tailwinds, sees 30% upside
- Macquarie cuts Macau gaming sector forecasts on weak GGR growth
- JPMorgan Upgrades Tokyo Century (8439:JP) to Overweight
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
